India's SII seeks govt intervention over COVID vaccine raw material import from USA
Shortage of raw materials from the USA could affect the scaling up of production of the Oxford-AstraZeneca (LSE: AZN) COVID-19 vaccine by the Pune-based Serum Institute of India (SII).
Chief executive Adar Poonawalla spoke at a World Bank panel that a US law is blocking the export of key items that could cause 'serious bottlenecks' in vaccine production.
The Indian vaccines giant has sought the Narendra Modi government's intervention to enable the Institute to import essential raw materials from the US for uninterrupted manufacturing and supply of COVID-19 vaccines.
The SII is producing the vaccine developed by AstraZeneca and Oxford University under its own brand name Covishield and also has agreements with some other developers to produce their vaccines. The SII is the world's largest vaccine manufacturer by volume.
US has invoked Defense Production Act
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze